<a href="https://laohu8.com/S/IDYA">IDEAYA Biosciences</a> Announces Phase 1 Trial Data Presentation for IDE849 in Small-Cell Lung Cancer at 2025 World Conference on Lung Cancer
IDEAYA Biosciences Inc., in collaboration with Jiangsu Hengrui Pharmaceuticals Co., Ltd., has announced an upcoming oral presentation of clinical efficacy and safety data for IDE849 (SHR-4849), a potential first-in-class DLL3-TOP1 antibody drug conjugate $(ADC)$. The data will be presented at the IASLC 2025 World Conference on Lung Cancer, scheduled for September 6-9, 2025, in Barcelona, Spain. The presentation will cover results from a Phase 1 trial conducted by Hengrui in China, involving over 70 small-cell lung cancer (SCLC) patients. IDEAYA is also preparing a poster presentation on pre-clinical synergy data between TOP1-payload based ADCs and its PARG inhibitor, IDE161, which could enhance the durability of ADC treatments. The U.S. Phase 1 trial of IDE849 in SCLC patients was initiated in the third quarter of 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IDEAYA Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: SF34459) on July 22, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。